Home » Stocks » TBIO

Translate Bio, Inc. (TBIO)

Stock Price: $22.58 USD -0.57 (-2.44%)
Updated Jan 27, 2021 2:57 PM EST - Market open
Market Cap 1.72B
Revenue (ttm) 91.31M
Net Income (ttm) -64.26M
Shares Out 73.18M
EPS (ttm) -1.01
PE Ratio n/a
Forward PE 29.67
Dividend n/a
Dividend Yield n/a
Trading Day January 27
Last Price $22.58
Previous Close $23.14
Change ($) -0.57
Change (%) -2.44%
Day's Open 22.64
Day's Range 22.01 - 23.89
Day's Volume 609,004
52-Week Range 7.01 - 27.56

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

-- MRT5005 is the first clinical-stage mRNA therapeutic with nebulized delivery to the lung and first to be administered in multiple doses for the treatment of a chronic genetic disease -- -- ...

The Motley Fool - 3 weeks ago

Big drugmakers could be attracted to these smaller players with promising pipelines.

Other stocks mentioned: BLUE, EDIT
Seeking Alpha - 3 weeks ago

TBIO is a leader in mRNA therapeutics. Its cystic fibrosis program has interim data from a phase 1 study.

Zacks Investment Research - 1 month ago

We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.

Other stocks mentioned: BNTX, INO, MRNA, NVAX, VXRT
GlobeNewsWire - 1 month ago

LEXINGTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformativ...

Zacks Investment Research - 2 months ago

In the race to develop a coronavirus vaccine, Pfizer and its partner BioNTech have a lead, closely followed by Moderna. However, four other biotechs, NVAX, TBIO, INO and VXRT, still hold poten...

Other stocks mentioned: INO, NVAX, VXRT
The Motley Fool - 2 months ago

Great efficacy results for mRNA COVID-19 vaccines so far could bode well for these three stocks.

Other stocks mentioned: ARCT, CVAC
GlobeNewsWire - 2 months ago

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformativ...

GlobeNewsWire - 2 months ago

-- Advances Phase 1/2 clinical trial of MRT5005 for the treatment of cystic fibrosis ( CF ) with resumption of COVID-impacted enrollment and dosing -- -- Presented promising preclinical data a...

Seeking Alpha - 3 months ago

Translate's Covid-Vaccine, And Other News: The Good, Bad And Ugly Of Biopharma

The Motley Fool - 3 months ago

The market leader in flu vaccines is trailing in the race to find an effective coronavirus vaccine.

Other stocks mentioned: SNY
Investors Business Daily - 3 months ago

Translate Bio and Sanofi announced positive preclinical results for their Covid-19 vaccine candidate in mice and non-human primates, and said human testing will start this quarter; TBIO rose. ...

Other stocks mentioned: SNY
GlobeNewsWire - 3 months ago

Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies

Other stocks mentioned: SNY
GlobeNewsWire - 3 months ago

- - Lead candidate MRT5005 leverages Translate Bio’s proprietary LNP and mRNA platform and is the o nly clinical - stage mRNA therapeutic in development for the treatment of CF -- - - Second C...

GlobeNewsWire - 4 months ago

LEXINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transforma...

GlobeNewsWire - 5 months ago

-- Expanded collaboration with partner Sanofi Pasteur for all infectious diseases further unites Translate Bio’s leading mRNA technology and large-scale manufacturing with Sanofi’s world class...

Business Wire - 5 months ago

LOS ANGELES--(BUSINESS WIRE)---- $TBIO #TBIO--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Translate Bio, Inc.

Zacks Investment Research - 5 months ago

Is (TBIO) Outperforming Other Medical Stocks This Year?

The Motley Fool - 5 months ago

If coronavirus vaccine development efforts are a race, then pharmaceutical companies will need to hurdle more than clinical trials to be successful.

Other stocks mentioned: ARCT, BNTX, MRNA
Zacks Investment Research - 6 months ago

On Translate Bio's (TBIO) Q2 earnings call, investor focus will be on the company's progress with the development of its multiple COVID-19 vaccine candidates in collaboration with Sanofi.

Zacks Investment Research - 6 months ago

Translate Bio, Inc. (TBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 6 months ago

LEXINGTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformat...

Zacks Investment Research - 6 months ago

Is (TBIO) Outperforming Other Medical Stocks This Year?

Seeking Alpha - 6 months ago

Translate Bio Is Much More Than Just A Covid-19 Vaccine Biotech

Zacks Investment Research - 6 months ago

Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.

Other stocks mentioned: ALPN, ATNM, PCRX
GuruFocus - 6 months ago

Guru adds to holding on the back of the slipping price

Zacks Investment Research - 6 months ago

Investors need to pay close attention to Translate Bio (TBIO) stock based on the movements in the options market lately.

The Motley Fool - 7 months ago

The clinical-stage vaccine developer, which is working on a COVID-19 vaccine candidate, announced it's selling more shares to the public.

Zacks Investment Research - 7 months ago

Translate Bio (TBIO) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.

GlobeNewsWire - 7 months ago

LEXINGTON, Mass., June 25, 2020 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially trans...

Benzinga - 7 months ago

Translate Bio (NASDAQ: TBIO) shares were trading lower Thursday after the company announced a $125-million proposed common stock offering after the close Wednesday.

Reuters - 7 months ago

Developing a COVID-19 vaccine in record time will be tough. Producing enough to end the pandemic will be the biggest medical manufacturing feat in history.

Other stocks mentioned: AZN, JNJ, MRNA, SNY
GlobeNewsWire - 7 months ago

LEXINGTON, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially trans...

Zacks Investment Research - 7 months ago

Translate Bio (TBIO) and Sanofi expand their tie-up to develop mRNA vaccines for infectious diseases. The deal boosts the company's cash resources significantly along with potential future rev...

Other stocks mentioned: SNY
The Motley Fool - 7 months ago

Major market benchmarks settled for modest gains on Tuesday.

Other stocks mentioned: INO, SNY
Benzinga - 7 months ago

Sanofi SA which is in the race to develop a vaccine for SARS-CoV-2, which causes COVID-19, is unveiling an accelerated timeline for the vaccine program it is pursuing with GlaxoSmithKline plc

Other stocks mentioned: SNY
The Motley Fool - 7 months ago

The company's collaboration with Sanofi is shifting into a higher gear.

Other stocks mentioned: SNY
Benzinga - 7 months ago

Shares of the small-cap mRNA therapeutics company Translate Bio Inc (NASDAQ: TBIO) were ripping higher Tuesday.

Other stocks mentioned: SNY
Zacks Investment Research - 7 months ago

Sanofi (SNY) and Translate Bio expand their tie-up to develop mRNA vaccines for infectious diseases. The companies are already developing a mRNA vaccine candidate to combat COVID-19.

Other stocks mentioned: SNY
24/7 Wall Street - 7 months ago

Sanofi S.A. (NASDAQ: SNY) and Translate Bio Inc.

Other stocks mentioned: SNY
Investors Business Daily - 7 months ago

Translate Bio stock rocketed Tuesday after the biotech inked a deal with Sanofi to develop vaccines for all infectious diseases. Before, the companies had a deal for five vaccines.

Other stocks mentioned: SNY
Yahoo Finance - 7 months ago

Sanofi expecting for approval on Covid-19 vaccine in the beginning of 2021, also European markets up

Yahoo Finance's Tom Belger reports on the latest news about Sanofi, European markets higher on recovery hopes and Wirecard's former CEO Markus Braun being arrested for misrepresenting accounts...

Other stocks mentioned: SNY
CNBC Television - 7 months ago

Sanofi CEO Paul Hudson on two-pronged approach to developing Covid-19 vaccine

Investors are watching the race to develop a coronavirus vaccine closely for signs of when the U.S. economy can begin to get back on track. Sanofi is one of the drugmakers leading the charge w...

Other stocks mentioned: SNY
Reuters - 7 months ago

French drugmaker Sanofi has agreed a potential $2 billion deal with U.S. biotech company Translate Bio to make vaccines, expanding their collaboration in development of an inoculation against ...

Other stocks mentioned: SNY
GlobeNewsWire - 7 months ago

-- The two companies will build upon their existing collaboration to pursue novel mRNA vaccines aimed at broadly addressing current and future infectious diseases -- -- Translate Bio to recei...

Investors Business Daily - 7 months ago

The race for a coronavirus vaccine is giving biotech companies like Moderna, BioNTech and Translate Bio the chance to prove a relatively new technology known as messenger RNA vaccines. The po...

Other stocks mentioned: BNTX, MRNA
Zacks Investment Research - 7 months ago

As of late, it has definitely been a great time to be an investor of Translate Bio

GlobeNewsWire - 8 months ago

LEXINGTON, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformati...

GuruFocus - 8 months ago

Sanofi’s (NASDAQ:SNY) decision to hedge its bet on developing a vaccine for Covid-19 has helped nearly double the year-to-date share price of a Boston-area therapeutics company.

GlobeNewsWire - 8 months ago

-- Pursuing development of mRNA vaccine against COVID-19 through expanded collaboration with Sanofi Pasteur -- -- Existing large-scale manufacturing capacity expected to help meet needs of ...

About TBIO

Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.

Industry
Biotechnology
IPO Date
Jun 28, 2018
CEO
Ronald C. Renaud Jr.
Employees
93
Stock Exchange
NASDAQ
Ticker Symbol
TBIO
Full Company Profile

Financial Performance

In 2019, Translate Bio's revenue was $7.80 million, an increase of 449.58% compared to the previous year's $1.42 million. Losses were -$113.29 million, 16.3% more than in 2018.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Translate Bio stock is "Strong Buy." The 12-month stock price forecast is 32.25, which is an increase of 42.86% from the latest price.

Price Target
$32.25
(42.86% upside)
Analyst Consensus: Strong Buy